Suvretta Capital Management Files 13D/A for Benitec Biopharma

TL;DR

Suvretta Capital Management updated its stake in Benitec Biopharma. Watch this space.

AI Summary

On November 18, 2024, Suvretta Capital Management, LLC filed an amendment (Amendment #2) to its Schedule 13D for Benitec Biopharma Inc. The filing indicates a change in beneficial ownership as of November 14, 2024. Suvretta Capital Management, LLC, along with group members Averill Madison Master Fund, Ltd. and Averill Master Fund, Ltd., are involved in this filing concerning Benitec Biopharma Inc.'s common stock.

Why It Matters

This filing signals a potential shift in control or significant investment strategy by Suvretta Capital Management in Benitec Biopharma, which could impact the company's stock performance and future direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or changes in control, introducing uncertainty and potential volatility.

Key Players & Entities

• Suvretta Capital Management, LLC (company) — Filing party
• Benitec Biopharma Inc. (company) — Subject company
• Averill Madison Master Fund, Ltd. (company) — Group member
• Averill Master Fund, Ltd. (company) — Group member
• Andrew Nathanson (person) — Authorized contact

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 08205P

Filing Documents

• s8147572b.htm (SC 13D/A) — 76KB
• 0000899140-24-001285.txt ( ) — 78KB

From the Filing

SC 13D/A 1 s8147572b.htm SCHEDULE 13D/A, AMENDMENT #2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Benitec Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 08205P209 (CUSIP Number) Andrew Nathanson General Counsel & Chief Compliance Officer Suvretta Capital Management, LLC 540 Madison Avenue, 7 th Floor New York, NY 10022 (212) 702-5205 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 14, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 08205P209 1 NAME OF REPORTING PERSONS Averill Master Fund, Ltd. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (see instructions) WC 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 12,679,779 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 12,679,779 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 12,679,779(1) 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 44.15%(1)(2) 14 TYPE OF REPORTING PERSON (see instructions) CO (1) Includes (i) 7,883,385 shares of Common Stock (as defined below) previously held, and (ii) 4,796,394 shares of Common Stock issuable upon the exercise of the warrants of the Issuer (as defined below), subject to the 49.9% ownership limitation with respect to such warrants as further described herein. (2) Based on 28,717,309 shares of Common Stock outstanding, which represents (i) 23,216,425 shares of Common Stock outstanding as of November 12, 2024, as indicated in the Issuer's Form 10-Q for the fiscal quarter ended September 30, 2024, plus (ii) 5,500,884 shares of Common Stock issuable upon the exercise of warrants of the Issuer, subject to the 49.9% ownership limitation with respect to such warrants as further described herein.. CUSIP No. 08205P209 1 NAME OF REPORTING PERSONS Averill Madison Master Fund, Ltd. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (see instructions) WC 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 1,650,158 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 1,650,158 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,650,158(1) 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.75%(1)(2) 14 TYPE OF REPORTING PERSON (see instructions) CO (1) Includes (i) 945,668 shares of Common Stock previously held, and (ii) 704,490 shares of Common Stock issuable upon the exercise of the warrants of the Issuer, subject to the 49.9% ownership limitation with respect to such warrants as further described herein.. (2) Based on 28,717,309 shares of Common Stock outstanding, which represents (i) 23,216,425 shares of Common Stock outstanding as of November 12, 2024, as indicated in the Issuer's Form 10-Q for the fiscal quarter ended September 30, 2024, plus (ii) 5,500,884 shares of Common Stock issuable upon the exercise of warrants of the Issuer, subject to the 49.9% ownership limitation with respect to such warrants as further described herein. CUSIP No. 08205P209 1 NAME OF REPORTING PERSONS Suvretta Capi

View Full Filing

View this SC 13D/A filing on SEC EDGAR